On October 6, Natera fell 3.04% in regular trading, at $411.33 per share, with turnover of $160 million. The decline follows the previous session's 3.73% gain triggered by the launch of a phase 3 breast cancer trial, as profit-taking pressure emerged after the positive catalyst was realized.

The newly launched phase 3 trial, in partnership with Alliance Foundation Trials, evaluates a molecular residual disease-guided treatment strategy for over 2,000 patients with ER-positive/HER2-negative early breast cancer, combining Genentech's giredestrant with longitudinal Signatera Genome MRD monitoring.

Despite the intraday pullback, multiple investment banks have recently raised their price targets on Natera, with RBC Capital increasing its target to $460 from $350 and UBS lifting its target to $435 from $290, reflecting sustained confidence in Natera's MRD testing franchise and expanding clinical applications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)